MX9803851A - Compuestos macrociclicos novedosos como inhibidores de metaloproteasas. - Google Patents

Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.

Info

Publication number
MX9803851A
MX9803851A MX9803851A MX9803851A MX9803851A MX 9803851 A MX9803851 A MX 9803851A MX 9803851 A MX9803851 A MX 9803851A MX 9803851 A MX9803851 A MX 9803851A MX 9803851 A MX9803851 A MX 9803851A
Authority
MX
Mexico
Prior art keywords
compounds
macrocyclic compounds
metalloprotease inhibitors
inhibitors
novel macrocyclic
Prior art date
Application number
MX9803851A
Other languages
English (en)
Inventor
Chu-Biao Xue
Robert Joseph Cherney
Carl Peter Decicco
William Frank Degrado
Xiaohua He
Carl Nicholas Hodge
Irina Cipora Jacobson
Ronald Louis Magolda
Elizabeth Catherine Arner
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of MX9803851A publication Critical patent/MX9803851A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invencion se refiere a moléculas macrocíclicas que inhiben las metaloproteinasas, incluyendo la agrecanasa, y a la produccion del factor de necrosis de tumor (TNF). En particular, los compuestos son inhibidores de las metaloproteinasas involucradas en la degradacion de tejidos y a inhibidores de la liberacion del factor de necrosis de tumor. La presente invencion también se refiere a composiciones farmacéuticas que comprenden dichos compuestos y a los métodos de uso de estos compuestos para el tratamiento de trastornos inflamatorios.
MX9803851A 1995-11-14 1998-05-14 Compuestos macrociclicos novedosos como inhibidores de metaloproteasas. MX9803851A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US668495P 1995-11-14 1995-11-14
US64690296A 1996-05-08 1996-05-08
US74343996A 1996-11-01 1996-11-01

Publications (1)

Publication Number Publication Date
MX9803851A true MX9803851A (es) 1998-09-30

Family

ID=27358171

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9803851A MX9803851A (es) 1995-11-14 1998-05-14 Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.

Country Status (17)

Country Link
EP (1) EP0863885A2 (es)
JP (1) JP2000502050A (es)
CN (1) CN1202161A (es)
BR (1) BR9611563A (es)
CA (1) CA2237524A1 (es)
CZ (1) CZ144798A3 (es)
EE (1) EE9800115A (es)
HR (1) HRP960533A2 (es)
HU (1) HUP0201479A2 (es)
IL (1) IL124366A0 (es)
LV (1) LV12167B (es)
MX (1) MX9803851A (es)
NO (1) NO982185L (es)
PL (1) PL326714A1 (es)
SI (1) SI9620120A (es)
SK (1) SK63498A3 (es)
WO (1) WO1997018207A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281352B1 (en) 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA9820B (en) * 1997-01-07 1998-07-02 Abbott Lab Macrocyclic inhibitors of matrix metalloproteinases and tnf x secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
HUP0101468A2 (hu) 1998-03-31 2001-08-28 Du Pont Pharmaceuticals Company Angiogenetikus rendellenességek leképzésére alkalmas szerek
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
WO1999064406A1 (en) 1998-06-11 1999-12-16 Du Pont Pharmaceuticals Company A process for the preparation of macrocyclic metalloprotease inhibitors
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
IL142958A0 (en) 1998-12-18 2002-04-21 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6649377B1 (en) 1999-05-10 2003-11-18 Syntex (U.S.A.) Llc Human aggrecanase and nucleic acid compositions encoding the same
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
CA2379445C (en) 2000-06-01 2007-08-21 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005044780A1 (ja) * 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
WO2010132494A1 (en) * 2009-05-11 2010-11-18 Ghosh Arun K Compounds and methods for treating aids and hiv infections
MX349366B (es) * 2011-05-19 2017-07-26 Centro Nac De Investigaciones Oncologicas (Cnio) Compuestos novedosos.
CN102276546B (zh) * 2011-05-31 2014-06-25 中国科学院广州生物医药与健康研究院 用作蛋白聚糖酶调节剂的化合物及其应用
CN108727293B (zh) * 2016-09-18 2021-05-11 广西师范大学 1，2，8-氧代二氮杂环壬-9-酮衍生物及其合成方法
CN113194954A (zh) 2018-10-04 2021-07-30 国家医疗保健研究所 用于治疗角皮病的egfr抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
US5427954A (en) * 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis

Also Published As

Publication number Publication date
JP2000502050A (ja) 2000-02-22
WO1997018207A3 (en) 1997-07-24
HUP0201479A2 (en) 2002-08-28
CA2237524A1 (en) 1997-05-22
CN1202161A (zh) 1998-12-16
IL124366A0 (en) 1998-12-06
EP0863885A2 (en) 1998-09-16
CZ144798A3 (cs) 1998-10-14
SI9620120A (sl) 1999-06-30
PL326714A1 (en) 1998-10-26
WO1997018207A2 (en) 1997-05-22
EE9800115A (et) 1998-10-15
NO982185D0 (no) 1998-05-13
HRP960533A2 (en) 1998-04-30
BR9611563A (pt) 1999-03-02
LV12167B (en) 1999-03-20
NO982185L (no) 1998-07-13
SK63498A3 (en) 1999-01-11
LV12167A (lv) 1998-11-20

Similar Documents

Publication Publication Date Title
MX9803851A (es) Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.
WO1999009000A3 (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
UA48939C2 (uk) Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки
FI961976A0 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
MXPA02010618A (es) Inhibidores de fosfatidilinositol 3-quinasa delta.
BG105880A (en) Compounds useful as anti-inflammatory agents
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
AU7566601A (en) Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
AU7385398A (en) Novel macrocyclic compounds as metalloprotease inhibitors
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
IL153147A0 (en) Phospholipid derivatives of valporic acid and mixtures thereof
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
MX9709361A (es) Monomero de 4.4-ciclohexan-1-ols disubstituido y compuestos relacionados.
EA199800372A1 (ru) Новые макроциклические соединения-ингибиторы
NO972906D0 (no) 4,4-(Disubstituerte)cykloheksan-1-ol-monomerer og beslektede forbindelser
MX9704740A (es) Monomeros de 3,3-(disustituido)ciclohexan-1-ol y compuestos relacionados.
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors